Relyvrio: ALS patients in the U.S. contend with $158K price tag

In September, Relyvrio became only the third drug approved in the U.S. for ALS, or amyotrophic lateral sclerosis, an incurable neurodegenerative disease that is usually fatal within five years. But patients and physicians who celebrated Relyvrio's approval several months ago are now contending with the obstacles posed by the U.S. health care system.

Related Keywords

China ,Cambridge ,Cambridgeshire ,United Kingdom ,Hopkinton ,Massachusetts ,United States ,Washington ,Chinese ,Jim Mourey ,Diana Zuckerman ,Layne Oliff ,Lou Gehrig ,Neil Thakur ,Sarah Nauser ,Becky Mourey ,Terry Heiman Patterson ,National Center ,Drug Administration ,Veterans Administration ,Health Research ,Temple University ,Amylyx Pharmaceutical ,